医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Ningbo NewBay Medical Technology Co., Ltd. Announces a License Agreement with Genentech

2020年01月27日 PM11:00
このエントリーをはてなブックマークに追加


 

NINGBO, China

Ningbo NewBay Medical Technology Co., Ltd., a subsidiary of Ningbo Tai Kang Medical Technology Co., Ltd. announced today that it has entered into a licensing agreement with Genentech, a member of the Roche Group, under which it has been granted the exclusive global rights to further develop and commercialize GDC-0570, a small molecule Pan-PIM inhibitor that is active against multiple myeloma and prostate cancer in preclinical models. PIM kinases regulate cell metabolism, growth and survival.

“We are very pleased to enter this global exclusive license agreement with Genentech. We look forward to working with medical experts and global regulatory agents to accelerate clinical development of this promising investigational medicine,” commented Dr. Zhenhai Shen, CEO of Ningbo NewBay Medical Technology Co., Ltd.

Under the agreement, Genentech will receive an upfront payment and will be eligible to receive milestone payments linked to clinical, regulatory and commercial successes, as well as royalty payments.

About GDC-0570

GDC-0570 is a small molecule Pan-PIM inhibitor discovered and developed by Genentech. PIM-1/2/3 are Serine/Threonine kinases which play an essential role in the regulation of signal transduction cascades. GDC-0570 is a potential first-in-class drug candidate.

About Ningbo NewBay Medical Technology Co., Ltd.

Ningbo NewBay Medical Technology Co., Ltd. is an oncology focused biopharma company based in China with global development capabilities. It is a wholly owned subsidiary of Ningbo Tai Kang Medical Technology Co., Ltd. NewBay and Tai Kang own the Greater China right for two EP4 antagonists from AskAt, Inc. and the global right for c-KIT inhibitor from AstraZeneca.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200127005369/en/

CONTACT

Ms. Mingyuan Yuan

myuan@newbaypharma.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作